BofA initiated coverage of Tempus AI with a Buy rating and $41 price target. By combining a patient’s molecular, clinical, and imaging data with its AI platform, Tempus delivers personalized therapy decisions and its platform is being monetized as a diagnostic offering, notes the analyst. Tempus has achieved “impressive scale in a short period of time” and serves a large total addressable market of at least $70B, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Largest borrow rate increases among liquid names
- CMS awards Tempus AI with ADLT status for xT CDx test
- Tempus AI receives 510(k) clearance for Tempus ECG-AF
- Tempus AI, United Therapeutics collaborate to study use of AI to detect PH risk
- Tempus AI receives 510(k) Premarket Notification for Tempus ECG-AF